Section Arrow
VTVT.NASDAQ
- vTv Therapeutics
Quotes are at least 15-min delayed:2026/01/04 22:16 EST
Regular Hours
Last
 39.6
-0.39 (-0.98%)
Day High 
40.14 
Prev. Close
39.99 
1-M High
41.49 
Volume 
23.21K 
Bid
16.03
Ask
39.77
Day Low
38.2201 
Open
40.14 
1-M Low
24.3 
Market Cap 
159.10M 
Currency 美元 
P/E -- 
%Yield -- 
10-SMA 37.12 
20-SMA 34.33 
50-SMA 29.27 
52-W High 41.49 
52-W Low 13.2 
Exchange NASDAQ 
Valuation Estimation
EPS (Current/Estimated)
-3.30/-4.01
Enterprise Value
159.10M
Balance Sheet
Book Value Per Share
17.91
Cash Flow
Cash Flow Yield
--
Income Statement
Total Revenue
1.02M
Operating Revenue Per Share
0.00
Industry Comparison
Code Name   Last Change Change (%) P/E P/E Range
OTLKOutlook Therapeutics0.66-0.92-58.23%0.58PE
MREOMereo BioPharma Group plc0.5104+0.0937+22.49%-- 
SLSSELLAS Life Sciences Group4.35+0.58+15.38%-- 
ASBPAspire Biopharma Holdings Inc.0.1369+0.005+3.79%-- 
RXRXRecursion Pharmaceuticals4.2+0.11+2.69%-- 
Industry overview quotes are at least 15 minutes delayed
Business Description
vTv Therapeutics Inc is a late-stage biopharmaceutical company focused on developing oral, small molecule drug candidates intended to help treat people living with diabetes and other chronic diseases. Its clinical pipeline is led by cadisegliatin, currently in a Phase 3 trial, a potential novel first-in-class oral liver-selective glucokinase activator being investigated for the treatment of type 1 diabetes. The group and its development partners are investigating multiple molecules across different indications for chronic diseases. Its product pipeline are HPP737, Azeliragon, TTP-RA, TTP273, HPP971 / HPP3033, and HPP593.
Information provided by: etnet
Terms and Conditions
Bank of China (Hong Kong) Limited
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Bank of China (Hong Kong) Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.